Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell...
Staff
4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Press Release 4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted...
Enzyvant Announces Merger with Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonologyCARY, N.C.,...
EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company’s U.S. Subsidiary
LYON, France, December 6, 2022 -- EDAP TMS SA (NASDAQ: EDAP) (the “Company”), the global leader in robotic energy-based therapies,...
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Achievement Allows IND-enabling Studies in 1H’2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune DiseasesMedia Release...
GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader...
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral...
AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis
-Next-generation PSGL-1 agonist antibody with clinically proven mechanism of action receives IND clearance- -Phase 1 clinical trial expected to launch...
HTG Technology Featured Across Numerous Abstracts at Upcoming Scientific Conferences
TUCSON, Ariz., Dec. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in...
HEXO Corp Announces Repayment of 8.0% Unsecured Convertible Debentures
Repayment strengthens HEXO’s balance sheet and positions it for sustainable growthThis news release constitutes a “designated news release” for the...
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
$500 Million Upfront Payment to Activate the Partnership for IvonescimabMenlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06,...
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
Professor Dr. med. Matthias Dobbelstein Professor Dr. med. Matthias DobbelsteinJerusalem, Dec. 06, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals...
Update on full-year outlook for 2022
Company announcement no. 26 – 22 6 December 2022 Update on full-year outlook for 2022 Based on the financial performance...
Symbeo, Inc. launches latest solution for today’s AP challenges
New platform for enterprise and mid-market-size organizations drives invoice automationPORTLAND, Ore., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Symbeo, Inc., a...
Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test
With 99% accuracy and within 30 minutes, institutions will simultaneously and accurately test residents, health workers and visitors for COVID-19...
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec....
Mindset Pharma to Participate in Upcoming Conferences in December 2022
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a...
Good Supply Cannabis Brand Launches ‘Peppermint Phatty’
New 510 Thread Vape Cartridge Now Available Across CanadaTORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or...
Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole
Strong support from high-quality new and existing investors provides capital for opelconazole development and pre-commercialization activities well beyond ongoing registration...